

Notice of Allowability

Application No.

10/014,485

Examiner

Karen A. Canella

Applicant(s)

COMB ET AL.

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the interview of January 17, 2006.
2. ☒ The allowed claim(s) is/are 2-4, 11-16, 21, 23-26, renumbered as 2, 1 and 3-14, respectively.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date Jan 10, 2006
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material

5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),
Paper No./Mail Date 20060306
7. ☒ Examiner's Amendment/Comment

8. ☐ Examiner's Statement of Reasons for Allowance

9. ☒ Other replacement pg. 3/4 of the #449 form of 10/20/2004 from the IDS filed 11/13/2001 indicating a publication year for reference CB*

Art Unit: 1643

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with James Cullem on January 17, 2006.

The application has been amended as follows:

Claims 1, 17,-20, 22 and 27-45 have been canceled.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 11 am to 10 pm, except Wed, Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karen A. Canella, Ph.D.

3/6/2006


KAREN A. CANELLA PH.D.
PRIMARY EXAMINER

replacement page 3 for the 1449 form of 10/20/2004

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
KAC	BF*	Sigma 1998 Catalog pages 1305 and 1309
	BG*	Upstate Biotechnology 1998 Catalog page 17
	BH*	Zymed Laboratories 1996-1997 General Catalog page 80
	BI*	Monoclonal Antibodies, Hybridomas: A New Deminsion in Biological Analyses, Kennett et al. (eds.), Plenum Press (1980)
	BJ*	Antibodies: A Laboratory Manyual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press (1988)
	BK*	Methods in Enzymology, Vol. 201, Protein Phosphorylation, Part B Analysis of Protein Phosphorylation, Protein Kinase Inhibitors and Protein Phosphatases, Hunter and Sefton (eds.), Academic Press, Inc. (1991), pages 3-547
	BL*	Songyang, et al., Molecular and Cellular Biology, 16:6486-6493 (1996)
	BM*	Upstate Biotechnology 2001 Catalog, page 221
	BN*	Cell Signaling Technology, 2000-2001 Catalog, page 14
	CA*	Alessi, et al., FEBS Lett. 399:333-338 (1996)
	CB*	Franke, et al. Cell 88:435-437, 1997
	CC*	Pap, et al., Bio. Chem. 273:19929-19932 (1998)
	CD*	Datta, et al., Cell 91:231-241 (1997)
	CE*	Brunet, et al., Cell, 96:857-868 (1999)
	CF*	Cardone, et al., Science, 282:1318-1321 (1998)
	CG*	Montminy, Annual Re. Biochem. 66:807-822 (1997)
	CH*	Songyang, et al., Current Biology 4:973-982 (1994)
	CI*	Alessi, et al., EMBO J. 15:6541-6551 (1996)
	CJ*	Dalby, et al., J. Biol. Chem. 273:1496-1505 (1998)
	CK*	Keranen, et al., Curr. Biol., 5:1395-1403 (1995)
	CL*	Peng, et al., Science, 277:1501-1508 (1997)

Publication
date is
1997
KAC
3/6/2006

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
KAC	BF*	Sigma 1998 Catalog pages 1303 and 1309
	BG*	Upstate Biotechnology 1998 Catalog page 17
	BH*	Zymed Laboratories 1996-1997 General Catalog page 80
	BI*	Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennett et al. (eds.), Plenum Press (1980)
	BJ*	Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press (1988)
	BK*	Methods in Enzymology, Vol. 201, Protein Phosphorylation, Part B Analysis of Protein Phosphorylation, Protein Kinase Inhibitors and Protein Phosphatases, Hunter and Sefton (eds.), Academic Press, Inc. (1991), pages 3-547
	BL*	Songyang, et al., Molecular and Cellular Biology, 16:6486-6493 (1996)
	BM*	Upstate Biotechnology 2001 Catalog, page 221
	BN*	Cell Signaling Technology, 2000-2001 Catalog, page 14
	CA*	Alessi, et al., FEBS Lett. 399:333-338 (1996)
	CB*	Frank, et al. Cell 88:435-437 (1997) <i>NEB</i> <i>plac</i>
	CC*	Pap, et al., Bio. Chem. 273:19929-19932 (1998)
	CD*	Datta, et al., Cell 91:231-241 (1997)
	CE*	Brunet, et al., Cell, 96:857-868 (1999)
	CF*	Cardone, et al., Science, 282:1318-1321 (1998)
	CG*	Montminy, Annual Re. Biochem. 66:807-822 (1997)
	CH*	Songyang, et al., Current Biology 4:973-982 (1994)
	CI*	Alessi, et al., EMBO J. 15:6541-6551 (1996)
	CJ*	Dalby, et al., J. Biol. Chem. 273:1496-1505 (1998)
	CK*	Keranen, et al., Curr. Biol., 5:1395-1403 (1995)
	CL*	Peng, et al., Science, 277:1501-1508 (1997)